Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Southwest Oncology Group (SWOG)

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.